US Pharma MarketingThe post Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal appeared first on Medical Device Network.
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal
Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio. The post Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal appeared first on Medical Device Network .
Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.
Source: Medical Device Network